Stephan Schann
Director Técnico/Científico/I+D en Domain Therapeutics SA .
Perfil
Stephan Schann is currently the Chief Scientific Officer at Domain Therapeutics SA since 2008.
He previously worked as a Team Leader at Evotec (UK) Ltd.
Dr. Schann obtained his graduate and doctorate degrees from the University of Strasbourg.
Cargos activos de Stephan Schann
| Empresas | Cargo | Inicio |
|---|---|---|
Domain Therapeutics SA
 Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | Director Técnico/Científico/I+D | 01/01/2008 |
Antiguos cargos conocidos de Stephan Schann.
| Empresas | Cargo | Fin |
|---|---|---|
Evotec (UK) Ltd.
 Evotec (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Evotec SE, Evotec (UK) Ltd. provides research and development on natural sciences and engineering. The company is based in Abingdon, UK and was founded in 1991. | Corporate Officer/Principal | - |
Formación de Stephan Schann.
| University of Strasbourg | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | Health Technology |
Evotec (UK) Ltd.
Evotec (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Evotec SE, Evotec (UK) Ltd. provides research and development on natural sciences and engineering. The company is based in Abingdon, UK and was founded in 1991. | Commercial Services |
- Bolsa de valores
- Insiders
- Stephan Schann
